1. Ribas A, , Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018; 359: 1350–55. doi: https://doi.org/10.1126/science.aar4060

2. Pasello G, , Pavan A, , Attili I, , Bortolami A, , Bonanno L, , Menis J, , et al.. Real world data in the era of immune checkpoint inhibitors (icis): increasing evidence and future applications in lung cancer. Cancer Treat Rev 2020; 87: 102031: S0305-7372(20)30069-4. doi: https://doi.org/10.1016/j.ctrv.2020.102031

3. Haslam A, , Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2019; 2: e192535. doi: https://doi.org/10.1001/jamanetworkopen.2019.2535

4. Tang S, , Qin C, , Hu H, , Liu T, , He Y, , Guo H, , et al.. Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells 2022; 11(3): 320. doi: https://doi.org/10.3390/cells11030320

5. Gadgeel S, , Rodríguez-Abreu D, , Speranza G, , Esteban E, , Felip E, , Dómine M, , et al.. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 2020; 38: 1505–17. doi: https://doi.org/10.1200/JCO.19.03136

6. Paz-Ares L, , Vicente D, , Tafreshi A, , Robinson A, , Soto Parra H, , Mazières J, , et al.. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 2020; 15: 1657–69: S1556-0864(20)30500-1. doi: https://doi.org/10.1016/j.jtho.2020.06.015

7. Gray JE, , Villegas A, , Daniel D, , Vicente D, , Murakami S, , Hui R, , et al.. Three-Year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from Pacific. J Thorac Oncol 2020; 15: 288–93: S1556-0864(19)33529-4. doi: https://doi.org/10.1016/j.jtho.2019.10.002

8. Bai R, , Li L, , Chen X, , Chen N, , Song W, , Cui J. Neoadjuvant and adjuvant immunotherapy: opening new horizons for patients with early-stage non-small cell lung cancer. Front Oncol 2020; 10: 575472. doi: https://doi.org/10.3389/fonc.2020.575472

9. Dromain C, , Beigelman C, , Pozzessere C, , Duran R, , Digklia A. Imaging of tumour response to immunotherapy. Eur Radiol Exp 2020; 4: 2. doi: https://doi.org/10.1186/s41747-019-0134-1

10. Davis AA, , Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 2019; 7: 278. doi: https://doi.org/10.1186/s40425-019-0768-9

11. Lantuejoul S, , Sound-Tsao M, , Cooper WA, , Girard N, , Hirsch FR, , Roden AC, , et al.. Pd-L1 testing for lung cancer in 2019: perspective from the IASLC pathology Committee. J Thorac Oncol 2020; 15: 499–519: S1556-0864(19)33847-X. doi: https://doi.org/10.1016/j.jtho.2019.12.107

12. Chiou VL, , Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015; 33: 3541–43. doi: https://doi.org/10.1200/JCO.2015.61.6870

13. Champiat S, , Dercle L, , Ammari S, , Massard C, , Hollebecque A, , Postel-Vinay S, , et al.. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017; 23: 1920–28. doi: https://doi.org/10.1158/1078-0432.CCR-16-1741

14. Vani V, , Regge D, , Cappello G, , Gabelloni M, , Neri E. Imaging of adverse events related to checkpoint inhibitor therapy. Diagnostics (Basel) 2020; 10(4): E216. doi: https://doi.org/10.3390/diagnostics10040216

15. Carter BW. Immunotherapy in lung cancer and the role of imaging. Semin Ultrasound CT MR 2018; 39: 314–21: S0887-2171(18)30019-2. doi: https://doi.org/10.1053/j.sult.2018.02.004

16. Hodi FS, , Ballinger M, , Lyons B, , Soria J-C, , Nishino M, , Tabernero J, , et al.. Immune-modified response evaluation criteria in solid tumors (imrecist): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol 2018; 36: 850–58. doi: https://doi.org/10.1200/JCO.2017.75.1644

17. Zhou L, , Zhang M, , Li R, , Xue J, , Lu Y. Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature. J Cancer Res Clin Oncol 2020; 146: 3269–79. doi: https://doi.org/10.1007/s00432-020-03360-1

18. Beer L, , Hochmair M, , Prosch H. Pitfalls in the radiological response assessment of immunotherapy. Memo 2018; 11: 138–43. doi: https://doi.org/10.1007/s12254-018-0389-x

19. Shroff GS, , Shroff S, , Ahuja J, , Truong MT, , Vlahos I. Imaging spectrum of adverse events of immune checkpoint inhibitors. Clin Radiol 2021; 76: 262–72: S0009-9260(20)30625-5. doi: https://doi.org/10.1016/j.crad.2020.11.117

20. Seymour L, , Bogaerts J, , Perrone A, , Ford R, , Schwartz LH, , Mandrekar S, , et al.. IRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143–52. doi: https://doi.org/10.1016/S1470-2045(17)30074-8

21. Di Giacomo AM, , Danielli R, , Guidoboni M, , Calabrò L, , Carlucci D, , Miracco C, , et al.. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58: 1297–1306. doi: https://doi.org/10.1007/s00262-008-0642-y

22. Park HJ, , Kim KW, , Pyo J, , Suh CH, , Yoon S, , Hatabu H, , et al.. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology 2020; 297: 87–96. doi: https://doi.org/10.1148/radiol.2020200443

23. Tazdait M, , Mezquita L, , Lahmar J, , Ferrara R, , Bidault F, , Ammari S, , et al.. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irrecist and irecist criteria. Eur J Cancer 2018; 88: 38–47: S0959-8049(17)31357-6. doi: https://doi.org/10.1016/j.ejca.2017.10.017

24. Sheikhbahaei S, , Marcus CV, , Sadaghiani MS, , Rowe SP, , Pomper MG, , Solnes LB. Imaging of cancer immunotherapy: response assessment methods, atypical response patterns, and immune-related adverse events, from the AJR special series on imaging of inflammation. AJR Am J Roentgenol 2022; 218: 940–52. doi: https://doi.org/10.2214/AJR.21.26538

25. Ma Y, , Wang Q, , Dong Q, , Zhan L, , Zhang J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res 2019; 9: 1546–53.

26. Fujimoto D, , Yoshioka H, , Kataoka Y, , Morimoto T, , Hata T, , Kim YH, , et al.. Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy. J Thorac Oncol 2019; 14: 468–74: S1556-0864(18)33418-X. doi: https://doi.org/10.1016/j.jtho.2018.10.167

27. Park HJ, , Kim KW, , Won SE, , Yoon S, , Chae YK, , Tirumani SH, , et al.. Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw Open 2021; 4: e211136. doi: https://doi.org/10.1001/jamanetworkopen.2021.1136

28. Ding P, , Wen L, , Tong F, , Zhang R, , Huang Y, , Dong X. Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer. Cancer Drug Resist 2022; 5: 147–64. doi: https://doi.org/10.20517/cdr.2021.104

29. Lin M, , Vanneste BGL, , Yu Q, , Chen Z, , Peng J, , Cai X. Hyperprogression under immunotherapy: a new form of immunotherapy response? -A narrative literature review. Transl Lung Cancer Res 2021; 10: 3276–91. doi: https://doi.org/10.21037/tlcr-21-575

30. Ferrara R, , Mezquita L, , Texier M, , Lahmar J, , Audigier-Valette C, , Tessonnier L, , et al.. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018; 4: 1543–52. doi: https://doi.org/10.1001/jamaoncol.2018.3676

31. Facchinetti F, , Lo Russo G, , Tiseo M, , Garassino MC, , Ferrara R. How to recognize and manage hyper-progression and pseudo- progression during immune checkpoint blockade in non-small cell lung cancer. Precis Cancer Med 2019; 2: 35. doi: https://doi.org/10.21037/pcm.2019.10.03

32. Lo Russo G, , Facchinetti F, , Tiseo M, , Garassino MC, , Ferrara R. Hyperprogressive disease upon immune checkpoint blockade: focus on non-small cell lung cancer. Curr Oncol Rep 2020; 22(5): 41. doi: https://doi.org/10.1007/s11912-020-00908-9

33. Humbert O, , Chardin D. Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy. Front Oncol 2020; 10: 566297. doi: https://doi.org/10.3389/fonc.2020.566297

34. Borcoman E, , Kanjanapan Y, , Champiat S, , Kato S, , Servois V, , Kurzrock R, , et al.. Novel patterns of response under immunotherapy. Ann Oncol 2019; 30: 385–96: S0923-7534(19)31083-X. doi: https://doi.org/10.1093/annonc/mdz003

35. Boutros C, , Tarhini A, , Routier E, , Lambotte O, , Ladurie FL, , Carbonnel F, , et al.. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; 13: 473–86. doi: https://doi.org/10.1038/nrclinonc.2016.58

36. Nishino M, , Hatabu H, , Hodi FS. Imaging of cancer immunotherapy: current approaches and future directions. Radiology 2019; 290: 9–22. doi: https://doi.org/10.1148/radiol.2018181349

37. Smith DA, , Radzinsky E, , Tirumani SH, , Guler E, , Petraszko A, , Kikano E, , et al.. Findings on chest CT performed in the emergency department in patients receiving immune checkpoint inhibitor therapy: single-institution 8-year experience in 136 patients. AJR Am J Roentgenol 2021; 217: 613–22. doi: https://doi.org/10.2214/AJR.20.24758

38. Sverzellati N, , Lynch DA, , Hansell DM, , Johkoh T, , King TE, , Travis WD. American thoracic society-european respiratory Society classification of the idiopathic interstitial pneumonias: advances in knowledge since 2002. Radiographics 2015; 35: 1849–71. doi: https://doi.org/10.1148/rg.2015140334

39. Voong KR, , Naidoo J. Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer. Lung Cancer 2020; 150: 249–51: S0169-5002(20)30596-1. doi: https://doi.org/10.1016/j.lungcan.2020.08.022

40. von Reibnitz D, , Chaft JE, , Wu AJ, , Samstein R, , Hellmann MD, , Plodkowski AJ, , et al.. Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. Adv Radiat Oncol 2018; 3: 391–98. doi: https://doi.org/10.1016/j.adro.2018.05.001

41. Johkoh T, , Lee KS, , Nishino M, , Travis WD, , Ryu JH, , Lee HY, , et al.. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the fleischner Society. Radiology 2021; 298: 550–66. doi: https://doi.org/10.1148/radiol.2021203427

42. Nishino M, , Ramaiya NH, , Awad MM, , Sholl LM, , Maattala JA, , Taibi M, , et al.. Pd-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 2016; 22: 6051–60. doi: https://doi.org/10.1158/1078-0432.CCR-16-1320

43. Montaudié H, , Pradelli J, , Passeron T, , Lacour J-P, , Leroy S. Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol 2017; 176: 1060–63. doi: https://doi.org/10.1111/bjd.14808

44. Beer L, , Hochmair M, , Kifjak D, , Haug AR, , Prayer F, , Mayerhoefer ME, , et al.. Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma. Wien Klin Wochenschr 2020; 132: 467–74. doi: https://doi.org/10.1007/s00508-020-01667-0

45. Cui P, , Liu Z, , Wang G, , Ma J, , Qian Y, , Zhang F, , et al.. Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study. Cancer Med 2018; 7: 4115–20. doi: https://doi.org/10.1002/cam4.1579

46. Isono T, , Kagiyama N, , Takano K, , Hosoda C, , Nishida T, , Kawate E, , et al.. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer 2021; 12: 153–64. doi: https://doi.org/10.1111/1759-7714.13736

47. Moda M, , Saito H, , Kato T, , Usui R, , Kondo T, , Nakahara Y, , et al.. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Thorac Cancer 2020; 11: 3576–84. doi: https://doi.org/10.1111/1759-7714.13703

48. Delaunay M, , Prévot G, , Collot S, , Guilleminault L, , Didier A, , Mazières J. Management of pulmonary toxicity associated with immune checkpoint inhibitors. Eur Respir Rev 2019; 28: 154: 190012. doi: https://doi.org/10.1183/16000617.0012-2019

49. Haddox CL, , Shenoy N, , Shah KK, , Kao JC, , Jain S, , Halfdanarson TR, , et al.. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol 2017; 28: 673–75. doi: https://doi.org/10.1093/annonc/mdw655

50. Picchi H, , Mateus C, , Chouaid C, , Besse B, , Marabelle A, , Michot JM, , et al.. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect. 2018;24(3):216-8.

51. Pradere P, , Michot JM, , Champiat S, , Danlos FX, , Marabelle A, , Lambotte O, , et al.. Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy. Eur J Cancer. 2017;75:308-9.

52. Osorio JC, , Ni A, , Chaft JE, , Pollina R, , Kasler MK, , Stephens D, , et al.. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583-9.

53. Choi YW, , Munden RF, , Erasmus JJ, , Joo Park K, , Chung WK, , Jeon SC, , et al.. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. RadioGraphics 2004; 24: 985–97. doi: https://doi.org/10.1148/rg.244035160

54. Shibaki R, , Akamatsu H, , Fujimoto M, , Koh Y, , Yamamoto N. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy. Ann Oncol. 2017;28(6):1404-5.

55. Nobashi TW, , Nishimoto Y, , Kawata Y, , Yutani H, , Nakamura M, , Tsuji Y, , et al.. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers. Br J Radiol 2020; 93: 1115: 20200409. doi: https://doi.org/10.1259/bjr.20200409

56. Azria D, , Magné N, , Zouhair A, , Castadot P, , Culine S, , Ychou M, , et al.. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005; 31: 555–70. doi: https://doi.org/10.1016/j.ctrv.2005.07.008

57. Teng F, , Li M, , Yu J. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications. BMC Med 2020; 18(1): 275. doi: https://doi.org/10.1186/s12916-020-01718-3

58. Pirker R, , Filipits M. Adjuvant therapy in patients with completely resected non-small-cell lung cancer: current status and perspectives. Clin Lung Cancer 2019; 20: 1–6: S1525-7304(18)30261-4. doi: https://doi.org/10.1016/j.cllc.2018.09.016

59. Naidoo J, , Nishino M, , Patel SP, , Shankar B, , Rekhtman N, , Illei P, , et al.. Immune-Related pneumonitis after chemoradiotherapy and subsequent immune checkpoint blockade in unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 2020; 21: e435–44: S1525-7304(20)30076-0. doi: https://doi.org/10.1016/j.cllc.2020.02.025

60. Chaft JE, , Dahlberg SE, , Khullar OV, , Edelman MJ, , Simone CB, , Heymach J, , et al.. EA5142 adjuvant nivolumab in resected lung cancers (anvil). JCO 2018; 36: TPS8581. doi: https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS8581

61. Paz-Ares L, , Hasan B, , Dafni U, , Menis J, , De Maio E, , Oselin K, , et al.. A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS). Annals of Oncology 2017; 28: ii23. doi: https://doi.org/10.1093/annonc/mdx085.013

62. Wang Y, , Zhou S, , Yang F, , Qi X, , Wang X, , Guan X, , et al.. Treatment-Related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 2019; 5: 1008–19. doi: https://doi.org/10.1001/jamaoncol.2019.0393

63. Jung HA, , Noh JM, , Sun J-M, , Lee S-H, , Ahn JS, , Ahn M-J, , et al.. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. Lung Cancer 2020; 146: 23–29: S0169-5002(20)30469-4. doi: https://doi.org/10.1016/j.lungcan.2020.05.035

64. Vansteenkiste J, , Naidoo J, , Faivre-Finn C, , Özgüroğlu M, , Villegas A, , Daniel D, , et al.. MA05.02 Pacific subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after crt. Journal of Thoracic Oncology 2018; 13: S370–71. doi: https://doi.org/10.1016/j.jtho.2018.08.350

65. Shaverdian N, , Thor M, , Shepherd AF, , Offin MD, , Jackson A, , Wu AJ, , et al.. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab. Cancer Med 2020; 9: 4622–31. doi: https://doi.org/10.1002/cam4.3113

66. Tonk EHJ, , van Lindert ASR, , Verhoeff JJC, , Suijkerbuijk KPM. Acute-Onset pneumonitis while administering the first dose of durvalumab. Case Rep Oncol 2019; 12: 621–24. doi: https://doi.org/10.1159/000502202

67. Durbin SM, , Mooradian MJ, , Fintelmann FJ, , Zubiri L, , Chute DF, , Kambadakone A, , et al.. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer 2020; 8(2): e001329. doi: https://doi.org/10.1136/jitc-2020-001329

68. Kim KW, , Ramaiya NH, , Krajewski KM, , Jagannathan JP, , Tirumani SH, , Srivastava A, , et al.. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013; 31: 1071–77. doi: https://doi.org/10.1007/s10637-013-9939-6

69. Calandri M, , Solitro F, , Angelino V, , Moretti F, , Veltri A. The role of radiology in the evaluation of the immunotherapy efficacy. J Thorac Dis 2018; 10: S1438–46. doi: https://doi.org/10.21037/jtd.2018.05.130

70. Tang YZ, , Szabados B, , Leung C, , Sahdev A. Adverse effects and radiological manifestations of new immunotherapy agents. BJR 2019; 92: 1093. doi: https://doi.org/10.1259/bjr.20180164

71. Mazzaschi G, , Bordi P, , Fioretzaki R, , Gnetti L, , Milanese G, , Tommasi C, , et al.. Nivolumab-induced Guillain-Barré syndrome coupled with remarkable disease response in a case of heavily pretreated lung adenocarcinoma. Clin Lung Cancer 2020; 21: e65–73: S1525-7304(19)30318-3. doi: https://doi.org/10.1016/j.cllc.2019.11.001

72. Cuzzubbo S, , Javeri F, , Tissier M, , Roumi A, , Barlog C, , Doridam J, , et al.. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 2017; 73: 1–8: S0959-8049(16)33068-4. doi: https://doi.org/10.1016/j.ejca.2016.12.001

73. Garon-Czmil J, , Petitpain N, , Rouby F, , Sassier M, , Babai S, , Yéléhé-Okouma M, , et al.. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French pharmacovigilance database. Sci Rep 2019; 9(1): 19419. doi: https://doi.org/10.1038/s41598-019-56026-5

74. Barroso-Sousa R, , Barry WT, , Garrido-Castro AC, , Hodi FS, , Min L, , Krop IE, , et al.. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018; 4: 173–82. doi: https://doi.org/10.1001/jamaoncol.2017.3064

75. Costa LB, , Queiroz MA, , Barbosa FG, , Nunes RF, , Zaniboni EC, , Ruiz MM, , et al.. Reassessing patterns of response to immunotherapy with PET: from morphology to metabolism. Radiographics 2021; 41: 120–43. doi: https://doi.org/10.1148/rg.2021200093

76. Palaskas N, , Lopez-Mattei J, , Durand JB, , Iliescu C, , Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 2020; 9(2): e013757. doi: https://doi.org/10.1161/JAHA.119.013757

77. Altan M, , Toki MI, , Gettinger SN, , Carvajal-Hausdorf DE, , Zugazagoitia J, , Sinard JH, , et al.. Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol 2019; 14: 1102–8: S1556-0864(19)30196-0. doi: https://doi.org/10.1016/j.jtho.2019.02.026

78. Amrane K, , Le Goupil D, , Quere G, , Delcroix O, , Gouva S, , Schick U, , et al.. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. Medicine (Baltimore) 2019; 98: 29: e16417. doi: https://doi.org/10.1097/MD.0000000000016417

79. Seith F, , Forschner A, , Schmidt H, , Pfannenberg C, , Gückel B, , Nikolaou K, , et al.. 18F-Fdg-Pet detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. Eur J N